A Phase I, Multicenter, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects With Relapsed or Refractory B-cell Malignancies.
Latest Information Update: 18 Jan 2024
At a glance
- Drugs Rocbrutinib (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Newave Pharmaceuticals
- 12 Dec 2023 Initial Results (n= 43 at data cut off 10 Jul 2023) assessing safety evaluation focusing on DLT evaluable pts, and efficacy evaluation focusing on the cohort of pts with CLL presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 10 Nov 2023 Planned End Date changed from 1 Jul 2023 to 31 Dec 2025.
- 10 Nov 2023 Planned primary completion date changed from 1 Jul 2023 to 31 Jul 2025.